MTNB on NYSE

Matinas BioPharma Holdings, Inc.

American pharmaceutical preparations company based in Bedminster.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Bespoke Extracts, Inc., China SXT Pharmaceuticals, Inc. or Dare Bioscience, Inc., or pick any stock.

TickerMTNB on NYSE
IndustryPharmaceutical Preparations
HeadquartersBedminster, United States
Incorporated inDE²
Business address1545 Route 206 South, Suite 302, Bedminster, Nj 07921²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-2168.4%Operating margin³

-2093.2%Net margin³

-65.6%Revenue growth, 2023³

-119.2%Return on equity⁴

-$15.5MFree cash flow³

Where the money goes

Where each dollar of revenue went, fiscal 2023

Research and development

Research and development100¢$14.5M

Out of $1.1M in revenue.³ The company lost money this year.

Financial statements

Revenue⁵⁶⁷⁸³$1.1M in 2023+1120% since 2019

Operating income⁵⁶⁷⁸³-$23.8M in 2023+26% since 2019

Net income⁵⁶⁷⁸³-$22.9M in 2023+32% since 2019

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁴

Period ending	2025-12-31	2024-12-31
Research and development	$85.0K	$11.4M
General and administrative	$6.9M	$8.7M
Impairment charges of goodwill and other intangible assets		$2.1M
Impairment charges of other assets		$2.3M
Total costs and expenses	$7.0M	$24.6M
Loss from operations	-$7.0M	-$24.6M
Change in fair value of warrant liability	-$3.2M
Gain on sale of assets	$37.0K
Other (expenses)/income, net	-$261.0K	$262.0K
Loss before tax	-$10.3M	-$24.3M
Income tax benefit		$80.0K
Net loss	-$10.3M	-$24.3M
Deemed dividend relating to warrant exchange	-$618.0K
Net loss attributable to common shareholders	-$11.0M	-$24.3M
Net loss per share - basic	-$2.00	-$4.98
Net loss per share - diluted	-$2.00	-$4.98
Weighted average common shares outstanding - basic	5.5M shares	4.9M shares
Weighted average common shares outstanding - diluted	5.5M shares	4.9M shares
Unrealized gain on securities available-for-sale		$221.0K
Other comprehensive gain, net of tax		$221.0K
Comprehensive loss	-$10.3M	-$24.0M

Total assets⁵⁶⁷⁸³$25.1M in 2023−38% since 2019

Total liabilities⁵⁶⁷⁸³$5.9M in 2023−19% since 2019

Shareholders’ equity⁶⁷⁸³⁴$19.2M in 2023−42% since 2019

Cash⁶⁷⁸³⁴$4.8M in 2023−78% since 2019

Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.⁴

Period ending	2025-12-31	2025-11-30	2024-12-31	2023-12-31
Cash and cash equivalents	$4.0M		$7.3M	$4.8M
Restricted cash security deposit	$50.0K		$50.0K
Prepaid expenses and other current assets	$26.0K		$691.0K
Total current assets	$4.1M		$8.0M
Leasehold improvements and equipment - net	$138.0K		$468.0K
Operating lease right-of-use assets - net	$531.0K	$207.0K	$1.7M
Finance lease right-of-use assets - net	$4.0K		$8.0K
In-process research and development	$2.3M		$2.3M
Restricted cash - security deposit	$200.0K		$200.0K
Total non-current assets	$3.1M		$4.6M
Total assets	$7.2M		$12.6M
Accounts payable	$315.0K		$95.0K
Accrued expenses and other liabilities	$452.0K		$1.8M
Operating lease liabilities - current	$694.0K		$761.0K
Financing lease liabilities - current	$2.0K		$5.0K
Total current liabilities	$1.5M		$2.7M
Deferred tax liability	$257.0K		$257.0K
Operating lease liabilities - net of current portion	$653.0K		$2.1M
Financing lease liabilities - net of current portion	$5.0K		$12.0K
Total non-current liabilities	$915.0K		$2.4M
Total liabilities	$2.4M		$5.1M
Common stock par value $0.0001 per share, 500,000,000 and 250,000,000 shares authorized at December 31, 2025 and 2024, respectively; 6,406,191 and 5,086,985 issued and outstanding as of December 31, 2025 and 2024, respectively	$1.0K		$1.0K
Additional paid-in capital	$215.6M		$207.4M
Accumulated deficit	-$210.8M		-$199.8M
Total stockholders equity	$4.8M		$7.6M	$19.2M
Total liabilities and stockholders equity	$7.2M		$12.6M
Preferred stock, par value	$0.00
Preferred stock, shares authorized	10.0M shares
Common stock, par value	$0.00		$0.00
Common stock, shares authorized	500.0M shares		250.0M shares
Common stock, shares issued	6.4M shares		5.1M shares
Common stock, shares outstanding	6.4M shares		5.1M shares

Period ending	2025-12-31	2025-11-30	2024-12-31	2023-12-31
Cash and cash equivalents	$4.0M		$7.3M	$4.8M
Restricted cash security deposit	$50.0K		$50.0K
Prepaid expenses and other current assets	$26.0K		$691.0K
Total current assets	$4.1M		$8.0M
Leasehold improvements and equipment - net	$138.0K		$468.0K
Operating lease right-of-use assets - net	$531.0K	$207.0K	$1.7M
Finance lease right-of-use assets - net	$4.0K		$8.0K
In-process research and development	$2.3M		$2.3M
Restricted cash - security deposit	$200.0K		$200.0K
Total non-current assets	$3.1M		$4.6M
Total assets	$7.2M		$12.6M
Accounts payable	$315.0K		$95.0K
Accrued expenses and other liabilities	$452.0K		$1.8M
Operating lease liabilities - current	$694.0K		$761.0K
Financing lease liabilities - current	$2.0K		$5.0K
Total current liabilities	$1.5M		$2.7M
Deferred tax liability	$257.0K		$257.0K
Operating lease liabilities - net of current portion	$653.0K		$2.1M
Financing lease liabilities - net of current portion	$5.0K		$12.0K
Total non-current liabilities	$915.0K		$2.4M
Total liabilities	$2.4M		$5.1M
Common stock par value $0.0001 per share, 500,000,000 and 250,000,000 shares authorized at December 31, 2025 and 2024, respectively; 6,406,191 and 5,086,985 issued and outstanding as of December 31, 2025 and 2024, respectively	$1.0K		$1.0K
Additional paid-in capital	$215.6M		$207.4M
Accumulated deficit	-$210.8M		-$199.8M
Total stockholders equity	$4.8M		$7.6M	$19.2M
Total liabilities and stockholders equity	$7.2M		$12.6M
Preferred stock, par value	$0.00
Preferred stock, shares authorized	10.0M shares
Common stock, par value	$0.00		$0.00
Common stock, shares authorized	500.0M shares		250.0M shares
Common stock, shares issued	6.4M shares		5.1M shares
Common stock, shares outstanding	6.4M shares		5.1M shares

Cash from operations⁵⁶⁷⁸³-$15.3M in 2023+8% since 2019

Capital spending⁵⁶⁷⁸³$218.0K in 2023−46% since 2019

Free cash flow⁵⁶⁷⁸³-$15.5M in 2023+7% since 2019

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁴

Period ending	2025-12-31	2024-12-31
Net loss	-$10.3M	-$24.3M
Depreciation and amortization	$32.0K	$365.0K
Net gain on disposal of assets	-$37.0K
Stock-based compensation expense	$1.0M	$3.2M
Loss on operating lease right-of-use assets modification	$241.0K
Amortization of operating lease right-of-use assets	$420.0K	$602.0K
Amortization of finance lease right-of-use assets	$4.0K	$5.0K
Amortization of bond premium		-$17.0K
Change in fair value of warrant liability	$3.2M
Impairment charges of goodwill and other intangible assets		$2.1M
Impairment charges of other assets		$2.3M
Income tax benefit		-$84.0K
Prepaid expenses and other current assets	$665.0K	$587.0K
Accounts payable	$220.0K	-$419.0K
Accrued expenses and other liabilities	-$1.4M	$356.0K
Operating lease liabilities	-$1.0M	-$655.0K
Net cash used in operating activities	-$7.0M	-$15.9M
Proceeds from sale of assets	$335.0K
Purchases of marketable debt securities		-$8.4M
Proceeds from sales of marketable debt securities		$17.6M
Net cash provided by investing activities	$335.0K	$9.2M
Gross proceeds from private placement of preferred stock and common stock warrants	$3.3M
Transaction costs paid pursuant to private placement	-$29.0K
Net proceeds from exercise of warrants	$129.0K
Net proceeds from public offerings of common stock and warrants		$9.2M
Payments of capital lease liability principal	-$9.0K	-$5.0K
Net cash provided by financing activities	$3.4M	$9.2M
Net (decrease)/increase in cash, cash equivalents and restricted cash	-$3.3M	$2.5M
Reclassification of warrants from liability to equity	$6.1M
Unrealized gain on marketable debt securities		$221.0K
Exchange of warrants for shares of common stock	$618.0K
Reduction of right-of-use assets and lease liabilities on lease termination	$488.0K

Compare Matinas BioPharma Holdings, Inc. with another company

Leadership

Who has led Matinas BioPharma Holdings, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Jerome D. Jabbour2017–now

Chief financial officer

20202025

Chief executive officerJerome D. Jabbour Mar 23, 2018 to now¹¹
Chief executive officerRoelof Rongen Mar 1, 2017 to Sep 11, 2017¹²
PresidentJerome D. Jabbour Mar 1, 2017 to now¹³
Chief financial officerKeith A. Kucinski Jan 4, 2019 to Dec 15, 2023¹⁴
Chief financial officerGary Gaglione Mar 1, 2017 to May 2, 2018¹⁵

Board members and other officers (21)

Chief Business OfficerThomas Hoover Dec 15, 2021 to Dec 15, 2023¹⁶
Chief Medical OfficerJames J. Ferguson Iii. Feb 27, 2019 to Dec 15, 2023¹⁷
Chief Development OfficerTheresa Matkovits Oct 16, 2018 to Dec 15, 2023¹⁸
OfficerAbdel A. Fawzy Mar 1, 2017 to Mar 1, 2017¹⁹
OfficerDouglas F. Kling Mar 1, 2017 to Mar 1, 2017²⁰
Chief Scientific OfficerRaphael J. Mannino Mar 1, 2017 to Dec 15, 2021²¹
Senior VP of ComplianceDominick Dipaolo Apr 21, 2017 to May 2, 2018²²
Board memberAn Evelyn D. Feb 7, 2025 to now²³
Board memberEdward Neugeboren Mar 17, 2025 to now²⁴
Board memberKeith Murphy Mar 17, 2025 to now²⁵
Board memberKathryn Penkus Corzo Nov 2, 2021 to Nov 3, 2023²⁶
Board memberNatasha Giordano Sep 15, 2020 to Nov 3, 2023²⁷
Board memberMatthew Wikler Jan 5, 2018 to Nov 3, 2023²⁸
Board memberJerome D. Jabbour Mar 23, 2018 to now¹¹
Board memberPatrick G. Lepore Sep 6, 2018 to Nov 10, 2020²⁹
Board memberAdam K. Stern Mar 1, 2017 to Aug 24, 2020³⁰
Board memberHerbert J. Conrad Mar 1, 2017 to Nov 3, 2023³¹
Board memberJames S. Scibetta Mar 1, 2017 to Nov 3, 2023³²
Board memberRoelof Rongen Mar 1, 2017 to Sep 11, 2017¹²
Board memberStefano Ferrari Mar 1, 2017 to Sep 7, 2017³³
Board memberEric J. Ende Apr 21, 2017 to Nov 3, 2023³⁴

Timeline

Mar 23, 2018New chief executive Jerome D. Jabbour becomes CEO¹¹
Mar 1, 2017New chief executive Roelof Rongen becomes CEO¹²
May 21, 2013Founded Matinas BioPharma Holdings, Inc. is founded³⁵

Filings

198 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 69 major events, 60 insider forms, 14 large holders, 1 private raises, 33 other. The latest 20:

Sep 28, 20268-K EDGAR
Sep 16, 20268-K EDGAR
Sep 4, 20268-K EDGAR
Aug 25, 2026425 EDGAR
Aug 13, 202610-Q EDGAR
Aug 13, 2026SCHEDULE 13D/A EDGAR
Aug 13, 20264 OWNERSHIP DOCUMENT EDGAR
Aug 13, 20264 OWNERSHIP DOCUMENT EDGAR
Aug 4, 2026425 EDGAR
Jul 30, 2026425 EDGAR
Jul 29, 2026425 EDGAR
Jul 24, 20268-K EDGAR
Jul 21, 2026425 EDGAR
Jul 16, 2026425 EDGAR
Jul 14, 2026SCHEDULE 13G EDGAR
Jul 13, 2026425 EDGAR
Jul 13, 20268-K EDGAR
Jun 26, 20268-K EDGAR
Jun 22, 2026424B7 EDGAR
Jun 16, 2026S-3 EDGAR

The 198 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 14 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

Feb 13, 2025Raised $1.6 million in a private offering of equity Form D: $3.3 million offered in all Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARMatinas BioPharma Holdings, Inc. filings on SEC EDGAR
2
SEC EDGARMatinas BioPharma Holdings, Inc. filings on SEC EDGAR
3
SEC EDGARMatinas BioPharma Holdings, Inc. 10-K for fiscal 2023
4
SEC EDGARMatinas BioPharma Holdings, Inc. 10-K for fiscal 2023
5
SEC EDGARMatinas BioPharma Holdings, Inc. 10-K for fiscal 2019
6
SEC EDGARMatinas BioPharma Holdings, Inc. 10-K for fiscal 2020
7
SEC EDGARMatinas BioPharma Holdings, Inc. 10-K for fiscal 2021
8
SEC EDGARMatinas BioPharma Holdings, Inc. 10-K for fiscal 2022
9
SEC EDGARMatinas BioPharma Holdings, Inc. 10-Q for fiscal 2026
10
SEC EDGARMatinas BioPharma Holdings, Inc. 10-Q for fiscal 2026
11
SEC EDGARJerome D. Jabbour, Chief executive officer
12
SEC EDGARRoelof Rongen, Chief executive officer
13
SEC EDGARJerome D. Jabbour, President
14
SEC EDGARKeith A. Kucinski, Chief financial officer
15
SEC EDGARGary Gaglione, Chief financial officer
16
SEC EDGARThomas Hoover, Chief Business Officer
17
SEC EDGARJames J. Ferguson Iii., Chief Medical Officer
18
SEC EDGARTheresa Matkovits, Chief Development Officer
19
SEC EDGARAbdel A. Fawzy, Officer
20
SEC EDGARDouglas F. Kling, Officer
21
SEC EDGARRaphael J. Mannino, Chief Scientific Officer
22
SEC EDGARDominick Dipaolo, Senior VP of Compliance
23
SEC EDGARAn Evelyn D., Board member
24
SEC EDGAREdward Neugeboren, Board member
25
SEC EDGARKeith Murphy, Board member
26
SEC EDGARKathryn Penkus Corzo, Board member
27
SEC EDGARNatasha Giordano, Board member
28
SEC EDGARMatthew Wikler, Board member
29
SEC EDGARPatrick G. Lepore, Board member
30
SEC EDGARAdam K. Stern, Board member
31
SEC EDGARHerbert J. Conrad, Board member
32
SEC EDGARJames S. Scibetta, Board member
33
SEC EDGARStefano Ferrari, Board member
34
SEC EDGAREric J. Ende, Board member
35
gleifMatinas BioPharma Holdings, Inc. is founded